menu
    • menu
    [{"orgOrder":0,"company":"The Valens Company","sponsor":"Harvest One Cannabis","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Approved","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"The Valens Company \/ Harvest One Cannabis","highestDevelopmentStatusID":"12","companyTruncated":"The Valens Company \/ Harvest One Cannabis"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Propella Therapeutics \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Capsaicin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Averitas Pharma \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Averitas Pharma \/ Grunenthal"}]

    Find Clinical Drug Pipeline Developments & Deals for Capsaicin

    Menu

    Capsaicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Averitas Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Averitas Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Grunenthal

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Grünenthal Completes Recruitment for QUTENZA® Post-Surgical Neuropathic Pain Trial

                            Details : Qutenza (capsaicin) topical patch is approved for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy, being investigated for post-surgical neuropathic pain.

                            Brand Name : CA-008

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 07, 2024

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Grunenthal

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Propella Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm)...

                            Details : Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-5 for the Greater China region. Topical CGS-200-5 has clinically been shown to significantly reduce OA knee pain.

                            Brand Name : CGS-200-5

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 07, 2022

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Averitas Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Averitas Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled in a Phase III study with QUTENZA® in Post-Surgical Neuropathic Pain

                            Details : The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.

                            Brand Name : Qutenza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 10, 2021

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The Valens Company

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            The Valens Company

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin,Cannabidiol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Harvest One Cannabis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            The Valens Agreement Manufacture and Distribute Leading Infused Topical Brand

                            Details : LivRelief is a growing line of cannabis-infused topical creams created using natural ingredients which utilize a proprietary transdermal delivery system, allowing cannabinoids to reach targeted areas and designed for deep penetration.

                            Brand Name : LivRelief

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 28, 2021

                            Lead Product(s) : Capsaicin,Cannabidiol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Harvest One Cannabis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth